Novo Nordisk just made a move that rattled Wall Street. The company slashed U.S. prices for Wegovy and warned investors that sales and profits could drop by as much as 13% this year. Shares plunged hard, wiping nearly $50 billion off its market value in a single trading session. CEO Mike Doustdar called the financial hit “painful but necessary,” framing it as an investment...